Diabetic nephropathy is also known as diabetic kidney disease. It is a kidney-related condition as a result of diabetes mellitus. Diabetes can damage the delicate filtering system of collecting waste from the blood inside the kidneys. Severe damage leads to kidney failure or other end-stage kidney conditions. One-fourth of diabetes patients are affected by diabetic nephropathy. Diabetic nephropathy if left untreated can lead to kidney failure and kidney failure is a serious complication. The only possible treatment for it is dialysis or a kidney transplant. 40% of kidney failure cases are a result of diabetic nephropathy. Diabetic nephropathy is a slowly progressing disease.
The first stage has very mild symptoms and the fifth stage has very serious symptoms and is a serious case of kidney failure.
Glomerular filtration rate (GFR): This is used to determine the stage of the kidney condition. This is vital as the treatment plan varies according to the stage one is diagnosed with. The important function of the kidney is to filter the blood. GFR is a test to check the functioning of the kidney, it gives the value of how much blood passes through the filters in the kidney.
Stage 1: Mildest symptoms. There is a little bit of damage to the kidneys but the functioning of the kidney is normal. It is characterized by a GFR equal to or above 90.
Stage 2: There is damage to the kidney leading to some loss of functions. It is characterized by a GFR value between 60 to 89.
Summary Researcher clinical trial report, “Diabetic Nephropathy Global Clinical Trials Review, H1, 2020" provides an overview of Diabetic Nephropathy Clinical trials scenario.
This report provides top line data relating to the clinical trials on Diabetic Nephropathy.
The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database.
Clinical trials database undergoes periodic update by dynamic process.
Diabetic nephropathy is known as the most significant impediment occurring in the kidney glomerulus which render the patient morbid or even worse in majority of the cases. Characterized by macroalbuminuria, diabetic nephropathy is diagnosed when more than 300 milligrams of albumin are present in the urine in a day. The global market for diabetic nephropathy was valued at US$ 2,262.2 million in 2014. Registering a steady CAGR of 5.6%, the global market is slated to attain US$ 3,145.9 million market value over the forecast period 2014-2020.
Key Market Dynamics
Prominence of diabetes in the world isn’t the solitary driver for growth of global diabetic nephropathy market. The market is also driven by growing expenditure for R&D in order to develop drugs for treating diabetic nephropathy. The occurrence of diabetic nephropathy is closely related hypertension, instable glomerular filtration rate and proteinuria, which are impacting the global market significantly. The importance of kidney glomerulus, which if implicated can spike up the mortality rate and morbidity in a given region, also urges patients to undertake treatment of diabetic nephropathy before the eleventh-hour. Unfortunately, the market’s growth is impaired when current medical technologies continue to be futile in terms of detecting diabetic nephropathy in early stages. Subjectively, the implications arising while opting combination therapies for treatment and coupling multiple models of treatment together is also inhibiting additional investments for pharmaceutical development. Procrastinated approval of such drugs is also jeopardizing the future prospects of companies producing drugs for treating diabetic nephropathy.
Report For Sample with Table of Contents@ https://www.researchreportinsights.com/report/sample/110114710/Diabetic-Nephropathy-market
Segment Analysis
Evidently, combination therapies are gaining popularity as a mode of treating diabetic nephropathy, but the growth of global market continues to be discerned upon the most prominent model of treatment, which is Disease Modifying Therapies (DMTs). Furthermore, the global diabetic nephropathy market is fragmented into DMTs such as G protein-coupled receptors, calcium channel blockers, endothelin-A receptor antagonist, diuretics, angiotensin-converting enzyme inhibitors, antioxidant inflammation modulator, angiotensin receptor blockers, connective tissue growth factor inhibitors, renin inhibitors and monocyte chemo-attractant proteins inhibitors. In 2014, the market value for global DMT market reached US$ 2,093.5 million, which is projected to increase at 5.8% CAGR to attain US$ 2,929.8 million by the end of forecast period. ACE inhibitors are slated to be the largest DMT segment in the global diabetic nephropathy market over the forecast period.
Request For Report Discount@ https://www.researchreportinsights.com/report/discount/110114710/Diabetic-Nephropathy-market
Regional Analysis
Considerable rise in diabetic population and soaring incidences of disorders associated with kidneys makes Asia’s diabetic nephropathy market grow rampantly. Nevertheless, North America dominates the global diabetic nephropathy market after recording US$ 931.0 million value in 2014, which is projected to reach US$ 1,302.0 million by 2020 after enduring an estimated 5.7% CAGR. Europe is slated to be the second-most leading regional market, owing to increasing expenditure of R&D for diabetic nephropathy treatment.
Key Market Players
Global leaders in pharmaceuticals industry continue to foray into the global market for diabetic nephropathy by instating research facilities and production plants for drugs. Although, developing drugs for treating diabetic nephropathy has been challenged by advent of alternative treatments and studies indicating adverse effects, thereby influencing the contribution of such companies in the global diabetic nephropathy market. Abbott Laboratories, Mitsubishi Tanabe Pharma Corporation, Novartis AG, Pfizer, Inc., Merck & Co., Inc., Sanofi, Reata Pharmaceuticals, Inc., AbbVie Inc., and Eli Lilly Company, among others, are some of the prominent players participating the growth of the global diabetic nephropathy market.
Report Analysis@ https://www.researchreportinsights.com/report/rd/110114710/Diabetic-Nephropathy-market
Kidney failure can occur as a result of ESRD, which can be life-threatening.What are the risk factors of Diabetic Nephropathy?The risk factors for diabetic nephropathy incorporate smoking, comorbidities and is more prevalent in people who are more than 62-65 years old.
Waste products can accumulate in the blood over time, causing symptoms.Swollen feet and ankles, darker urine, shortness of breath are some of the symptoms presented in the later stages.
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) can help to lower blood pressure, protect kidney function, and prevent further damage.Also, Read- Diabetic Nephropathy Market CompaniesWhat is Diabetic Nephropathy Market Research?The increase in market size is a direct consequence of an increase in prevalent cases of diabetes, thereby a rise in a number of cases of Diabetic Kidney Disease.
In addition to this, increase in R activity, awareness programs for diabetes and kidney-related issues in the 7MM.The prevalence of diabetes worldwide has extended epidemic magnitudes and is expected to affect millions of people in the upcoming years.
It is also one of the most significant long-term complications in terms of morbidity and mortality for individual patients with diabetes.What is Diabetic Nephropathy Treatment Market?Treatment of patients with diabetic nephropathy can be divided into four major areas: cardiovascular risk reduction, glycemic control, blood pressure control, and inhibition of the renin-angiotensin system (RAS).
Recommendations for therapy include targeting a hemoglobin A1c concentration < 7% and blood pressure < 140/90 mm Hg with therapy anchored around the use of a RAS-blocking agent.
